SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on December 18, 2024. The filing discloses the entry into a material definitive agreement regarding a new equity financing mechanism. The company is incorporated in Delaware and trades on The NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed relates to the potential capital raise:
- Maximum Offering Size: Up to $8,500,000 in aggregate common stock.
- Commission Fee: 3% of the gross sales price of shares sold.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Agreements
On December 18, 2024, the Company entered into an "At The Market" (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. Key terms include:
- Agreement Type: Sales Agreement allowing for "at-the-market" offerings under Rule 415 of the Securities Act.
- Underlying Registration: Based on a shelf registration statement (Form S-3) declared effective by the SEC on December 17, 2024.
- Sales Method: Shares may be sold directly on The NASDAQ Capital Market, through market makers, or in negotiated transactions at prevailing market prices.
- Obligations: The Company is not obligated to sell any shares, and the Agent is not required to sell any specific amount, though they will use commercially reasonable efforts.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds from the offering for working capital and general corporate purposes. The agreement includes customary representations, warranties, and indemnification obligations. The offering will terminate upon the termination of the Sales Agreement by either party. No specific forward-looking guidance regarding future revenue or earnings was provided in this filing.
Key Facts for Investor Verification
- Verify the current share price and trading volume to assess the potential dilution impact of selling up to $8.5 million in shares.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific termination clauses and price limitations.
- Confirm the Company's current cash position and burn rate to understand the urgency of the working capital needs.
- Check for any subsequent filings indicating the actual volume of shares sold under this agreement.